Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDG-PET Directed Intervention in Locally Advanced Gastric Cancer
NCT02485834Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2015
- Primary completion
- Aug 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Nov 2015; status: terminated.
02
Drugs
docetaxelirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02485834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485834.